Trial Profile
Safety and efficacy of intravitreal ranibizumab in patients with neovascular age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Apr 2017
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- 27 Apr 2017 New trial record